Crossmark

Height outcomes in children with growth hormone deficiency and idiopathic short stature treated concomitantly with growth hormone and aromatase inhibitor therapy: data from the ANSWER program

Crossref DOI link: https://doi.org/10.1186/s13633-020-00089-z

Published Online: 2020-10-06

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miller, Bradley S. http://orcid.org/0000-0003-3663-5473
Ross, Judith

Ostrow, Vlady
Funding

Funding for this research was provided by:

Novo Nordisk Inc (N/A)
License Information

Text and Data Mining valid from 2020-10-06

Version of Record valid from 2020-10-06
More Information

Article History

Received: 11 January 2020

Accepted: 30 August 2020

First Online: 6 October 2020

Ethics approval and consent to participate

: Approval was obtained from relevant ethics committees, and written consent was obtained from all participants or guardians/legal representatives. ANSWER was conducted in accordance with the Declaration of Helsinki, Guideline for Good Pharmacoepidemiology Practices, and regulatory requirements.

: Not applicable as all data were pseudonymized.

: BSM – Research support: Abbvie, Alexion, Amgen, Novo Nordisk, OPKO, Orphan Reach, Sandoz, Sanofi Genzyme, and Takeda; Consultancy: Ascendis, BioMarin, Bluebird Bio, GeneScience, Novo Nordisk, Pfizer, Sandoz, Sanofi Genzyme, Soleno, Takeda and Tolmar. JR – Research support: Novo Nordisk; Consultancy: Novo Nordisk; Data Safety Monitoring Board: OPKO. VO – Employee of Novo Nordisk.

Document is current

Any future updates will be listed below